Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Work In Process (2023 - 2024)

Seres Therapeutics (MCRB) has disclosed Work In Process for 2 consecutive years, with $48.1 million as the latest value for Q2 2024.

  • Quarterly Work In Process rose 911.85% to $48.1 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $48.1 million through Jun 2024, up 911.85% year-over-year, with the annual reading at $25.2 million for FY2023, N/A changed from the prior year.
  • Work In Process hit $48.1 million in Q2 2024 for Seres Therapeutics, up from $37.3 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $48.1 million in Q2 2024 to a low of $4.8 million in Q2 2023.